About Ngb Laboratories Private Limited
Data last updated: 13 March 2026
Ngb Laboratories Private Limited is a private limited company based in Surat, Gujarat, India, recognised as a startup by DPIIT. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 17 February 2014, the company has been in operation for over 12 years.
Registered with ROC Ahmedabad under CIN U24100GJ2014PTC078771.
Capital: an authorised share capital of ₹12 Cr and a paid-up capital of ₹11.75 Cr. It is led by directors including Harishkumar Natverlal Bachkaniwala and Manishkumar Harishkumar Bachkaniwala.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 31 Prajit Row House B/H. Nehru Nagar Umra Athwalines, Surat, Gujarat, India – 395007.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.72 Cr, a growth of 5% compared to the previous year.
The company has a workforce of approximately 3 employees as per the latest available data.
The company is associated with 1 brand - Ngb Laboratories. As per MCA filings, the company has satisfied charges of ₹31.7 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ngblaboratories.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address31 Prajit Row House B/H. Nehru Nagar Umra Athwalines, Surat, Gujarat, India – 395007
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Ngb Laboratories Private Limited
Ngb Laboratories Private Limited operates one associated brand: NGB Laboratories. These brands represent Ngb Laboratories Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| NGB Laboratories develops and manufactures a range of pharmaceutical products, including antibiotics. | ngblaboratories.com |
Competitors & Alternatives of Ngb Laboratories Private Limited
Brands and companies operating in the same space as Ngb Laboratories Private Limited include Nephron Pharmaceuticals, Suanfarma, Enzene Biosciences and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Nephron Pharmaceuticals
|
Sterile pharmaceutical products are manufactured and contract services are provided. | Florida, Puerto Rico, United States | 1937 |
Suanfarma
|
Generics, nutraceuticals, and APIs are developed by Suanfarma. | Madrid, Spain, Spain | 1993 |
Enzene Biosciences
|
Company specializing in development of Biosimilars | Pune, India, India | 2006 |
Quotient Sciences
|
APIs and finished dosage forms are developed and manufactured. | Nottingham, United Kingdom, United Kingdom | 1990 |
Hybio Pharmaceutical
|
Polypeptide drugs and APIs are developed and manufactured. | Shenzhen, China, China | 1998 |
Aiolos Bio
|
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions | Boston, United States, United States | 2023 |
Kardigan
|
Biotech company developing personalized medicines for cardiovascular diseases | San Francisco, United States, United States | 2023 |
AmbioPharm
|
CDMO and analytical services for peptide development are provided. | North Augusta, United States, United States | 2006 |
Business Activity of Ngb Laboratories Private Limited
Ngb Laboratories Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Ngb Laboratories Private Limited
Ngb Laboratories Private Limited is audited by A G H R & CO for the financial year 2022. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| A G H R & CO | blur-value | blur-value | blur-value |
Board of Directors of Ngb Laboratories Private Limited
Ngb Laboratories Private Limited is currently managed by 6 directors, with 5 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Harishkumar Natverlal Bachkaniwala | Director | 17 Feb 2014 | 12 Years 4 Months | Current |
| Manishkumar Harishkumar Bachkaniwala | Director | 17 Feb 2014 | 12 Years 4 Months | Current |
| Jasmin Mansukhlal Bachkaniwala | Director | 19 Feb 2014 | 12 Years 4 Months | Current |
| Dharmesh Pravin Kharwar | Director | 04 Apr 2019 | 7 Years 3 Months | Current |
| Mansukhlal Natverlal Bachkaniwala | Director | 19 Feb 2014 | 12 Years 4 Months | Current |
Financials of Ngb Laboratories Private Limited FY 2025 filings available
Ngb Laboratories Private Limited reported revenue of ₹1.72 Cr (up 5% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Ngb Laboratories Private Limited
As of FY 2022, Ngb Laboratories Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Ngb Laboratories Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Jul 2020 | Others | ₹1 Cr | Satisfied |
| 20 Dec 2017 | Others | ₹8.25 Cr | Satisfied |
| 03 Mar 2015 | The Sutex Co-Operative Bank Ltd | ₹2.35 Cr | Satisfied |
| 03 Mar 2015 | The Sutex Co-Operative Bank Ltd | ₹1 Cr | Satisfied |
| 23 Feb 2015 | Others | ₹19.1 Cr | Satisfied |
Total charge records: 5 View all charges
Employees and EPFO Compliance at Ngb Laboratories Private Limited
Ngb Laboratories Private Limited has a workforce of 3 employees as of Apr 09, 2024.
Employee Count & EPFO Data of Ngb Laboratories Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Ngb Laboratories Private Limited
GSTIN & GST Filing Data of Ngb Laboratories Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Ngb Laboratories Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Ngb Laboratories Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Ngb Laboratories Private Limited
MSME Payment Delays by Ngb Laboratories Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Ngb Laboratories Private Limited
Subsidiaries & Group Companies of Ngb Laboratories Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Ngb Laboratories Private Limited with ownership details.
MCA Filings & Documents of Ngb Laboratories Private Limited
MCA Filings & Documents of Ngb Laboratories Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Ngb Laboratories Private Limited
Frequently Asked Questions about Ngb Laboratories Private Limited
Ngb Laboratories Private Limited is an active private limited company in the pharma sector based in Surat, Gujarat, India. It was incorporated on 17 February 2014 (12+ years old) and is registered under CIN U24100GJ2014PTC078771. The company has 3 employees.
Ngb Laboratories Private Limited reported revenue of ₹1.72 Cr for FY 2025 (up 5.00% YoY).
The current directors of Ngb Laboratories Private Limited are:
The primary industry of Ngb Laboratories Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes, Ngb Laboratories Private Limited is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Ngb Laboratories Private Limited can be reached at the registered office: 31 Prajit Row House BH. Nehru Nagar Umra Athwalines, Surat, Gujarat, India – 395007, or through the website ngblaboratories.com.